Advertisement
Login
Committee Connection
Home
Commentary
Sandra M. Swain, MD, FACP
Clement Adebamowo, MD, ScD
Jonathan Berek, MD, MMS
Douglas Blayney, MD
Anees Chagpar, MD
John Cox, DO, MBA, FACP
Don S. Dizon, MD, FACP
Linda R. Duska, MD
Michael Fisch, MD, MPH
L. Michael Glodé, MD
David L. Graham, MD
Guest Commentary
Heather M. Hylton, MS, PA-C
International Perspectives
Abdul-Rahman Jazieh, MD, MPH
Michael P. Link, MD
Robert Miller, MD
Beverly Moy, MD, MPH
Luke Nordquist, MD, FACP
George W. Sledge, Jr., MD
Michael A. Thompson, MD, PhD
Jamie H. Von Roenn, MD
Peter Yu, MD
View All
Magazine
Online Exclusives
Cover Story
Current Controversies in Oncology
From the Society
Member News
More Features
Book Reviews
View All
Interests
Conquer Cancer Foundation
Education
EHR
Fellows and Junior Faculty
General Interest
International Insights
Leadership Voices
Meetings
Membership Experience
Policy
Practice
Research
View All
Groups
Group Directory
Managing Emails & Invitations (Group Creator Only)
View All
Forums
Member News & Networking (ASCO Member Only)
Fellows and Junior Faculty (ASCO Member Only)
Policy: ASCO in Action (ASCO Member Only)
Practice
ASCO University
International Insights
Community Clinical Investigators
Electronic Health Records (EHR)
Education and Meeting News
Cancer News -- Hot Topics in the Media
Conquer Cancer Foundation
General Interest
View All
Member Directory
About
ASCO Connection
Bloggers
Editorial Board
Search
Latest Forum Activity
Conquer Cancer Foundation
Past Grant Recipient Shows a New Immune-based Therapy Is Effective for a Variety of Cancers
read more...
ASCO Admin
Seeking Submissions for Expressions of Hope Calendar
read more...
Anil Sood
Re: Ovarian Cancer: ASCO Tumor Boards
read more...
Robert Mannel
Ovarian Cancer: ASCO Tumor Boards
read more...
Conquer Cancer Foundation
Our Reach Is Global. Our Impact Is Personal.
read more...
ASCO in Action
CMS Revises NCCI Edits on CPT® Code 96361
read more...
Conquer Cancer Foundation
Foundation Recognizes ASCO AM Research; Announces Diversity in Oncology Awards
read more...
ASCO International Affairs
Pathology at Moi Teaching and Referral Hospital, a partial success story
read more...
ASCO Admin
American Urological Association Issues New Recommendations on PSA Screening
read more...
Conquer Cancer Foundation
From One to Many, Here and Around the World
read more...
Welcome to the ASCO Connection Forums
Please read the
Forum & Comment Guidelines
before proceeding.
Search
Home
Previous
Next
6/11/2012 6:21 PM
ASCO Admin
Joined: 3/1/2011
Posts: 401
MEK162 Appears To Target Two Common Melanoma Mutations, According to Phase II Data
Medpage Today
reports on results of a study
presented at the ASCO Annual Meeting, in which investigative agent MEK162 appeared to cause a disease response in patients with late-stage melanoma who have
BRAF
or
NRAS
mutations.
Page 1 of 1
Previous
Next
Log in
required to see "reply" and "create thread" links.